Table 1.
Summary and comparison of selected studies on text messages for medication adherence.
| Study | Disease focus | Design | Theory | Frequency of messages | Tailored messaging |
| Mulvaney et al [35], 2012 | T1Da | Pilot RCTb | Nc |
|
Yd |
| Osborn and Mulvaney [36], 2013 | T2De | Development and feasibility study | N |
|
Y |
| Arora et al [37], 2014 | T2D | RCT | N |
|
N |
| Bobrow et al [38], 2014 | HTNf | Pragmatic RCT | N |
|
Y |
| Gatwood et al [39], 2014 | DMg | Development and feasibility study | Y |
|
Y |
| Islam et al [40], 2014 | T2D | RCT | Y |
|
N |
| Buis et al [41], 2015 | HTN | RCT | Y |
|
Y |
| Bobrow et al [42], 2016 | HTN | Pragmatic RCT | Y |
|
Y |
| Farris et al [43], 2016 | HTN | Cross-sectional | N | —h | N |
| Nelson et al [22], 2016 | T2D | Cross-sectional | Y |
|
Y |
| Abaza and Marschollek [44], 2017 | T2D | Pilot RCT | N |
|
N |
| Haramiova et al [45], 2017 | HTN | Pragmatic RCT | N |
|
Y |
| Huo et al [46], 2017 | DM and CHDi | RCT | Y |
|
Y |
| Varleta et al [47], 2017 | HTN | RCT | Y |
|
N |
| Bobrow et al [48], 2018 | HTN | RCT | Y |
|
N |
| Prayaga et al [49], 2018 | Chronic disease | RCT | N |
|
Y |
| Angellotti et al [50], 2019 | T2D and HTN | Single-arm trials | N |
|
Y |
| Bartlett et al [51], 2019 | T2D | Cross-sectional | Y | — | N |
| Farmer et al [52], 2019 | T2D | Randomized feasibility trial protocol | Y |
|
Y |
| Gong et al [53], 2019 | CVDj | Pilot study of a cluster-randomized controlled trial | Y |
|
N |
| Huo et al [54], 2019 | CHD and T2D | RCT | Y |
|
Y |
| Kassavou et al [55], 2019 | HTN | Cross-sectional | Y |
|
Y |
| Waller et al [56], 2019 | T2D | RCT | Y |
|
Y |
| Zheng et al [57], 2019 | CHD | RCT | Y |
|
Y |
| Adu et al [58], 2020 | T1D and T2D | Development and feasibility study | Y | — | Y |
| Bartlett et al [59], 2020 | T2D | Message development and fidelity study | Y | — | N |
| Bhandari et al [60], 2020 | HTN | RCT | Y |
|
N |
| Champoux et al [61], 2020 | HTN | Development and feasibility study | Y |
|
Y |
| Jahan et al [62], 2020 | HTN | RCT | N |
|
N |
| Kundury and Hathur [63], 2020 | T2D | Pilot RCT | N |
|
N |
| Li et al [64], 2020 | Overweight | RCT | Y |
|
Y |
| Owolabi et al [65], 2020 | DM | RCT | N |
|
Y |
| Sadanshiv et al [66], 2020 | T2D | RCT | Y |
|
Y |
| Schoenthaler et al [67], 2020 | T2D | Cross-sectional | Y |
|
Y |
| Zhai et al [68], 2020 | HTN | RCT | N |
|
N |
| Campos et al [69], 2021 | HTN | Pilot RCT | N |
|
Y |
| Farmer et al [70], 2021 | T2D | RCT | Y |
|
Y |
| Lauffenburger et al [71], 2021 | T2D | Pragmatic RCT | N | — | N |
| Leon et al [72], 2021 | T2D | RCT | Y |
|
Y |
| Sharp et al [73], 2021 | T2D | RCT | N |
|
N |
| Bartlett et al [74], 2022 | T2D | RCT feasibility | Y |
|
Y |
| Bhandari et al [75], 2022 | HTN | Pilot RCT | Y |
|
Y |
| Farmer et al [76], 2022 | T2D | Protocol of RCT | Y |
|
N |
| Kershaw et al [77], 2022 | Nonspecific chronic disease | Pilot RCT | N | — | N |
| Levin et al [78], 2022 | HTN among patients with bipolar | 2-stage RCT | Y |
|
Y |
| Mandal et al [79], 2022 | T2D | RCT | N |
|
Y |
| Philis-Tsimikas et al [80], 2022 | T2D | RCT | Y |
|
N |
| Van Emmenis et al [81], 2022 | HTN | Cross-sectional | Y |
|
Y |
| Asgary et al [82], 2023 | HTN | Cross-sectional | Y |
|
N |
| SPRINT INDIA trial collaborators [83], 2023 | Recurrent stroke prevention | RCT | N |
|
Y |
| Zamanillo-Campos et al [84], 2023 | T2D | Pragmatic RCT | Y |
|
Y |
| Zamanillo-Campos et al [85], 2024 | T2D | RCT | Y |
|
Y |
aT1D: type 1 diabetes.
bRCT: randomized controlled trial.
cN: did not use theory or tailored messaging on text messages for medication adherence.
dY: used theory or tailored messaging on text messages for medication adherence.
eT2D: type 2 diabetes.
fHTN: hypertension.
gDM: diabetes mellitus.
hNot available.
iCHD: coronary heart disease.
jCVD: cardiovascular disease.